Argenx stock at EUR 745.20, 0.05 percent below its recent high

Published on 10/12/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Argenx stock costs EUR 745.20 on October 12, 2026. Results are due October 22, 2026 after USD 1.54 billion in second-quarter revenue.

Key points in brief

Argenx stock was at EUR 745.20 at Lang & Schwarz on October 12, 2026.
The price stood 0.05 percent below the recent EUR 745.60 high reported for October 9, 2026.
Third-quarter results are scheduled for October 22, 2026.
Second-quarter revenue reached USD 1.54 billion and diluted earnings per share were USD 7.32.

Extremmakro: Iridisierende blaue und violette Flüssigkeitstropfen auf einem Glasobjektträger, kristallscharfe Mitte mit weichem Bokeh, wissenschaftliche Abstraktion — Argenx NL0010832176 Extremmakro zeigt irisierende Flüssigkeitstropfen auf einem wissenschaftlichen Glas-Objektträger unter Laborlicht, Illustration mit AI erstellt.

Argenx stock was at EUR 745.20 at Lang & Schwarz on October 12, 2026 at 2:35 p.m. CEST. That price stood 0.05 percent below the recent EUR 745.60 high reported for October 9, 2026, putting the intraday quote close to the latest visible peak.

Price remains near its recent high

The latest euro quote is materially above the EUR 728.40 closing level reported for argenx on October 9, 2026 at Euronext Brussels. That comparison uses separate venues and dates, so it describes placement rather than a daily change for the Lang & Schwarz quote.

Argenx has a USD 51.3 billion market capitalization, a trailing price to earnings ratio of 31.94 and a 52-week USD range of 661.85 to 1,072.75, based on the latest primary-market context dated October 9, 2026. The euro quote and the US-dollar valuation are separate market measures.

Valuation follows strong revenue growth

MarketBeat reported that argenx generated USD 1.54 billion of revenue and USD 7.32 of diluted earnings per share in the second quarter of 2026. Revenue exceeded the cited USD 1.45 billion consensus, while earnings per share were above the USD 5.86 consensus.

That operating comparison is the key counterweight to the recent clinical setback. Markets Insider reported on October 9, 2026 that Baird lowered its Argenx target from USD 932.00 to USD 823.00 while keeping a Neutral rating after the UNITY study was discontinued.

Third-quarter date is October 22

argenx is scheduled to report third-quarter 2026 results on October 22, 2026, according to RTTNews. The date gives the market a defined test for whether VYVGART demand can sustain the revenue pace shown in the second quarter.

Comparison with peers

Argenx: , P/E 31.94, market capitalization USD 51.3 billion

UCB (Euronext Brussels, EUR): plus 1.13 percent, P/E 17.82, market capitalization EUR 39.2 billion

Roche Holding (SIX, USD): plus 1.35 percent, P/E 23.51, market capitalization USD 344.8 billion

Trading remains close to the peak

The Lang & Schwarz quote was EUR 745.20 on October 12, 2026 at 2:35 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Argenx stock.